Literature DB >> 26991997

Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.

Yang Liu1, Yanzhen Yin1, Jingya Zhang1, Krystle Nomie2, Liang Zhang2, Dezhi Yang1, Michael L Wang2, Guisen Zhao1.   

Abstract

A series of 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives was synthesized and evaluated as Akt inhibitors by optimization of a weak screening lead (1). Typically, compounds 5q and 5t significantly improved the Akt1 inhibitory potency with IC50 values of 18.0 and 21.3 nM, respectively, with desirable antiproliferative effect against the cell lines LNCaP and PC-3. The inhibitors 5q and 5t might serve as lead compounds for further exploration of Akt inhibitors as anticancer agents.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Akt; Anticancer; Docking; Pyrrolopyrimidines

Mesh:

Substances:

Year:  2016        PMID: 26991997     DOI: 10.1002/ardp.201500427

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  1 in total

1.  Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant.

Authors:  Daoguang Zhang; Dongdong Tong; Dezhi Yang; Jing Sun; Fenghe Zhang; Guisen Zhao
Journal:  Medchemcomm       Date:  2018-07-03       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.